Faricimab, an intravitreal vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor, is approved in the US and Europe for the treatment of macular oedema secondary to retinal vein occlusion.[99]ClinicalTrials.gov. A study to evaluate the efficacy and safety of faricimab in participants with macular edema secondary to branch retinal vein occlusion (BALATON). ClinicalTrials.gov ID: NCT04740905. Jul 2023 [internet publication].
https://clinicaltrials.gov/study/NCT04740905
[100]ClinicalTrials.gov. A study to evaluate the efficacy and safety of faricimab in participants with macular edema secondary to central retinal or hemiretinal vein occlusion (COMINO). ClinicalTrials.gov ID: NCT04740931. Aug 2023 [internet publication].
https://clinicaltrials.gov/study/NCT04740931